Ricardo Gargini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9111577/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer's disease. Human Molecular Genetics, 2016, 25, 792-806.	1.4	134
3	Slower Dynamics and Aged Mitochondria in Sporadic Alzheimer's Disease. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	1.9	95
4	Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ. Oncogene, 2017, 36, 3515-3527.	2.6	69
5	Benefit of Oleuropein Aglycone for Alzheimer's Disease by Promoting Autophagy. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-12.	1.9	66
6	The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. Science Translational Medicine, 2020, 12, .	5.8	46
7	WIP Drives Tumor Progression through YAP/TAZ-Dependent Autonomous Cell Growth. Cell Reports, 2016, 17, 1962-1977.	2.9	44
8	Novel Functions of the Neurodegenerative-Related Gene Tau in Cancer. Frontiers in Aging Neuroscience, 2019, 11, 231.	1.7	40
9	Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target. Cancers, 2020, 12, 1622.	1.7	29
10	Oncogenic dependence of glioma cells on kish/TMEM167A regulation of vesicular trafficking. Glia, 2019, 67, 404-417.	2.5	21
11	A comprehensive overview on the molecular biology of human glioma: what the clinician needs to know. Clinical and Translational Oncology, 2020, 22, 1909-1922.	1.2	21
12	Tumor-Derived Pericytes Driven by EGFR Mutations Govern the Vascular and Immune Microenvironment of Gliomas. Cancer Research, 2021, 81, 2142-2156.	0.4	20
13	Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-12.	1.9	16
14	Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype. Cancers, 2020, 12, 3230.	1.7	16
15	Blood-Brain Barrier Disruption: A Common Driver of Central Nervous System Diseases. Neuroscientist, 2022, 28, 222-237.	2.6	13
16	The EGFR-TMEM167A-p53 Axis Defines the Aggressiveness of Gliomas. Cancers, 2020, 12, 208.	1.7	12
17	IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas. Neurotherapeutics, 2022, 19, 408-420.	2.1	2